Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

The tetravalent guanylhydrazone CNI-1493 blocks the toxic effects of interleukin-2 without diminishing antitumor efficacy.

Kemeny MM, Botchkina GI, Ochani M, Bianchi M, Urmacher C, Tracey KJ.

Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4561-6.

2.

Improving responses in hepatomas with circadian-patterned hepatic artery infusions of recombinant interleukin-2.

Kemeny MM, Alava G, Oliver JM.

J Immunother (1991). 1992 Nov;12(4):219-23.

PMID:
1477073
3.

A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma.

Atkins MB, Redman B, Mier J, Gollob J, Weber J, Sosman J, MacPherson BL, Plasse T.

Clin Cancer Res. 2001 Mar;7(3):486-92.

4.

CNI-1493 attenuates hemodynamic and pro-inflammatory responses to LPS.

Molina PE, Qian L, Schuhlein D, Naukam R, Wang H, Tracey KJ, Abumrad NN.

Shock. 1998 Nov;10(5):329-34.

PMID:
9840647
5.

Macrophage inhibitor, semapimod, reduces tumor necrosis factor-alpha in myocardium in a rat model of ischemic heart failure.

Kherani AR, Moss GW, Zhou H, Gu A, Zhang G, Schulman AR, Fal JM, Sorabella R, Plasse T, Rui L, Homma S, Burkhoff D, Oz MC, Wang J.

J Cardiovasc Pharmacol. 2004 Dec;44(6):665-71.

PMID:
15550785
6.

Tumour necrosis factor mediates the survival benefit of interleukin 2 in a murine pulmonary metastases model.

Fraker DL, Thom AK, Doherty GM, Langstein HN, Buresh CM, Norton JA.

Surg Oncol. 1992 Feb;1(1):1-9.

PMID:
1341229
8.

Protection against lung damage in reduced-size liver transplantation.

Franco-Gou R, Rosell├│-Catafau J, Peralta C.

Crit Care Med. 2006 May;34(5):1506-13.

PMID:
16540955
9.

CNI-1493 prolongs survival and reduces myocyte loss, apoptosis, and inflammation during rat cardiac allograft rejection.

Yang X, Szabolcs M, Minanov O, Ma N, Sciacca RR, Bianchi M, Tracey KJ, Michler RE, Cannon PJ.

J Cardiovasc Pharmacol. 1998 Jul;32(1):146-55.

PMID:
9676735
10.

Intra-arterial administration of TNF-alpha followed by arterial ablation is an effective therapy for a regionally confined TNF-resistant rat mammary adenocarcinoma.

Badgwell BD, Valentino DJ, Jeffes EB, Dieffenbach K, Dulkanchainun SB, Yamamoto RS, Granger GA, Jakowatz JG, Carson WE.

Cancer Immunol Immunother. 2003 Jan;52(1):10-6. Epub 2002 Nov 1.

PMID:
12536235
11.

Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.

Margolin K, Atkins M, Sparano J, Sosman J, Weiss G, Lotze M, Doroshow J, Mier J, O'Boyle K, Fisher R, Campbell E, Rubin J, Federighi D, Bursten S.

Clin Cancer Res. 1997 Apr;3(4):565-72.

12.

A novel inhibitor of inflammatory cytokine production (CNI-1493) reduces rodent post-hemorrhagic vasospasm.

Bowman G, Bonneau RH, Chinchilli VM, Tracey KJ, Cockroft KM.

Neurocrit Care. 2006;5(3):222-9.

PMID:
17290094
13.

Inhibition of p38 mitogen activate kinase attenuates the severity of pancreatitis-induced adult respiratory distress syndrome.

Denham W, Yang J, Wang H, Botchkina G, Tracey KJ, Norman J.

Crit Care Med. 2000 Jul;28(7):2567-72.

PMID:
10921596
14.

Induction of interleukin-1beta, tumour necrosis factor-alpha and apoptosis in mouse organs by amphotericin B is neutralized by conjugation with arabinogalactan.

Falk R, Hacham M, Nyska A, Foley JF, Domb AJ, Polacheck I.

J Antimicrob Chemother. 2005 May;55(5):713-20. Epub 2005 Apr 6.

15.

Results of a dose-intense phase 1 study of a combination chemotherapy regimen with cisplatin and epidoxorubicin including medroxyprogesterone acetate and recombinant interleukin-2 in patients with inoperable primary lung cancer.

Mantovani G, Macci├▓ A, Lai P, Massa E, Massa D, Mulas C, Succu G, Mudu MC, Manca G, Versace R, Pisano A.

J Immunother. 2000 Mar-Apr;23(2):267-74.

PMID:
10746553
16.

Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model.

Chen B, Timiryasova TM, Andres ML, Kajioka EH, Dutta-Roy R, Gridley DS, Fodor I.

Cancer Gene Ther. 2000 Nov;7(11):1437-47.

17.

[Therapeutic effects of human interleukin 10 gene transfer on severe acute pancreatitis in rats, an experimental study].

Wang D, Jin D, Wu Z, Zou W, Xu D, Zheng Z, Liu X.

Zhonghua Yi Xue Za Zhi. 2002 Jun 25;82(12):844-7. Chinese.

PMID:
12126536
18.
19.

Anti-tumor effects of paeonol in a HepA-hepatoma bearing mouse model via induction of tumor cell apoptosis and stimulation of IL-2 and TNF-alpha production.

Sun GP, Wang H, Xu SP, Shen YX, Wu Q, Chen ZD, Wei W.

Eur J Pharmacol. 2008 Apr 28;584(2-3):246-52. doi: 10.1016/j.ejphar.2008.02.016. Epub 2008 Feb 15.

PMID:
18329639
20.

Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma?

Le Cesne A, Vassal G, Farace F, Spielmann M, Le Chevalier T, Angevin E, Valteau-Couanet D, Fizazi K, Cojean I, Llombard A, Tursz T, Escudier B.

J Immunother. 1999 May;22(3):268-77.

PMID:
10335487
Items per page

Supplemental Content

Write to the Help Desk